Making the discoveries that defeat cancer

  • Home |
  • About Us  |
  • Research  |
  • Enterprise  |
  • Education  |
  • Jobs  |
  • Support Us  |
  • News  |
  • Contact Us
  • Home »
  • Support Us »
  • Opportunities for support

Opportunities for support

As a non-profit organisation, we rely on the generosity of our donors and supporters to:

  • fund new buildings and equipment for research
  • invest in start-up research teams
  • support the training of the cancer research leaders of the future

Developing personalised treatments for cancer is at the very heart of the ICR’s strategy and our scientists and clinicians are at the forefront of research in this field.

Our current funding priorities are:

  • the new Centre for Cancer Imaging to speed up the development of new cancer treatments and assess their effectiveness without the need for surgery
  • equipment to create a Tumour Profiling Unit, to enhance our understanding of tumour cells. This will allow us to take a more personalised approach to diagnosis and treatment
  • funding for PhD students, to enable them to perfect their skills under the guidance of the world’s best cancer scientists, and increase the impact of their own research

We are extremely grateful to the many thousands of individuals and organisations who have already helped us in our mission to make the discoveries that defeat cancer. Read some of their stories here.

Donate now

  • Opportunities for support
  • Development news
  • Everyman appeal
  • Donate
  • Remember us in your Will
  • Take part
  • Become a corporate partner
  • Contact the Development team

Professor Alan Ashworth, CEO

"Personalised medicine involves treating patients with drugs that specifically target those alternations, making the treatment more effective and causing fewer side-effects"


Last updated: 12 September 2012

Home of everyman FRSB
  • Contacts  | 
  • Privacy  | 
  • Terms and Conditions  | 
  • Accessibility  | 
  • Feedback  | 
  • Cookies  | 
  • Status
  • ICR News RSS Feed
  • Find us on Facebook
  • Follow us on Twitter